Clinical Trial VICCMEL1263


Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma

Principal Investigator(s)

Mark Kelley


  • Protocol No. VICCMEL1263
  • Open Date: 01/08/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: Local
  • Objective: The primary objective of the study is to identify markers of intrinsic resistance to B-RAF targeted therapy in B-RAF mutation-positive melanoma.
  • Disease Sites: Melanoma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics; Surgery
  • Drugs: GSK1120212; GSK2118436
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01701037
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.